Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

582 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Therapeutic Effects and Mechanisms of Action of Rifaximin in Gastrointestinal Diseases.
DuPont HL. DuPont HL. Mayo Clin Proc. 2015 Aug;90(8):1116-24. doi: 10.1016/j.mayocp.2015.04.016. Epub 2015 Jul 8. Mayo Clin Proc. 2015. PMID: 26162610 Review.
Rifaximin: a nonabsorbed antimicrobial in the therapy of travelers' diarrhea.
DuPont HL, Ericsson CD, Mathewson JJ, Palazzini E, DuPont MW, Jiang ZD, Mosavi A, de la Cabada FJ. DuPont HL, et al. Among authors: dupont mw. Digestion. 1998 Nov-Dec;59(6):708-14. doi: 10.1159/000007580. Digestion. 1998. PMID: 9813398 Clinical Trial.
Zaldaride maleate, an intestinal calmodulin inhibitor, in the therapy of travelers' diarrhea.
DuPont HL, Ericsson CD, Mathewson JJ, Marani S, Knellwolf-Cousin AL, Martinez-Sandoval FG. DuPont HL, et al. Gastroenterology. 1993 Mar;104(3):709-15. doi: 10.1016/0016-5085(93)91005-3. Gastroenterology. 1993. PMID: 8440431 Clinical Trial.
Pathogenesis of traveler's diarrhea.
DuPont HL. DuPont HL. Chemotherapy. 1995;41 Suppl 1:33-9. doi: 10.1159/000239395. Chemotherapy. 1995. PMID: 7671645
Prevention of travelers' diarrhea with rifaximin in US travelers to Mexico.
Martinez-Sandoval F, Ericsson CD, Jiang ZD, Okhuysen PC, Romero JH, Hernandez N, Forbes WP, Shaw A, Bortey E, DuPont HL. Martinez-Sandoval F, et al. Among authors: dupont hl. J Travel Med. 2010 Mar-Apr;17(2):111-7. doi: 10.1111/j.1708-8305.2009.00385.x. J Travel Med. 2010. PMID: 20412178
Enteroaggregative Escherichia coli diarrhea in travelers: response to rifaximin therapy.
Infante RM, Ericsson CD, Jiang ZD, Ke S, Steffen R, Riopel L, Sack DA, DuPont HL. Infante RM, et al. Among authors: dupont hl. Clin Gastroenterol Hepatol. 2004 Feb;2(2):135-8. doi: 10.1016/s1542-3565(03)00322-7. Clin Gastroenterol Hepatol. 2004. PMID: 15017618 Clinical Trial.
New concepts on intestinal microbiota and the role of the non-absorbable antibiotics with special reference to rifaximin in digestive diseases.
Bajaj JS, Barbara G, DuPont HL, Mearin F, Gasbarrini A, Tack J. Bajaj JS, et al. Among authors: dupont hl. Dig Liver Dis. 2018 Aug;50(8):741-749. doi: 10.1016/j.dld.2018.04.020. Epub 2018 Apr 27. Dig Liver Dis. 2018. PMID: 29807873 Review.
The accessory gene regulator-1 as a therapeutic target for C. difficile infections.
Darkoh C, DuPont HL. Darkoh C, et al. Among authors: dupont hl. Expert Opin Ther Targets. 2017 May;21(5):451-453. doi: 10.1080/14728222.2017.1311863. Epub 2017 Apr 3. Expert Opin Ther Targets. 2017. PMID: 28338356 Free PMC article. No abstract available.
Intestinal decontamination inhibits TLR4 dependent fibronectin-mediated cross-talk between stellate cells and endothelial cells in liver fibrosis in mice.
Zhu Q, Zou L, Jagavelu K, Simonetto DA, Huebert RC, Jiang ZD, DuPont HL, Shah VH. Zhu Q, et al. Among authors: dupont hl. J Hepatol. 2012 Apr;56(4):893-9. doi: 10.1016/j.jhep.2011.11.013. Epub 2011 Dec 13. J Hepatol. 2012. PMID: 22173161 Free PMC article.
Antimicrobial Susceptibility of Staphylococcus Isolates from the Skin of Patients with Diarrhea-Predominant Irritable Bowel Syndrome Treated with Repeat Courses of Rifaximin.
DuPont HL, Wolf RA, Israel RJ, Pimentel M. DuPont HL, et al. Antimicrob Agents Chemother. 2016 Dec 27;61(1):e02165-16. doi: 10.1128/AAC.02165-16. Print 2017 Jan. Antimicrob Agents Chemother. 2016. PMID: 27795384 Free PMC article. No abstract available.
582 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page